I recently contributed a post about AstraZeneca’s open approach to innovation and how we’re working with external partners to progress our research. One of these examples was Bayer HealthCare, with whom we’re sharing respective early research know-how and chemistry assets for selected drug targets proposed on each other’s behalf. Since then, we’ve managed to agree an extension to this collaboration, for a further three years.
This sort of peer-to-peer partnership was an industry first when it was initiated back in 2010. Sharing our respective compound libraries enables each party to identify promising new starting points for their respective drug discovery research. Both ourselves and Bayer have had some promising potential for early drug discovery research so far, which is why we’re lengthening the partnership into 2016.
We’re always looking to improve our drug discovery efforts through external collaborations. When innovation is key to our success, collaboration allows us to go further. For example, we can access a wider set of chemical starting points for projects, which I would liken to looking for a book in the library, rather than just checking on your own bookshelves.